Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report. Issue 1 (16th November 2022)

• Record Type: Journal Article
• Authors: Cheung, Verna; Michelis, Fotios V.; Sibai, Hassan
• Is Part Of: EJHaem. Volume 4:Issue 1(2023)
• Page Start: 269
• Page End: 272
• Publication Date: 2022-11-16
• Subjects: allogenic stem cell transplant -- hypomethylating agent -- myeloid lineage chimerism -- primary myelofibrosis; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.611
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due to advancing age, declined functional status, donor unavailability, toxicities associated with a second ASCT. Herein, we report the first case of utilizing initially azacitidine and subsequently oral decitabine + cedazuridine (decitabine), in the context of relapsed PMF post‐ASCT. Utilizing both hypomethylating agents provided disease control and improved donor/myeloid lineage chimerism levels, and the patient also remained transfusion independent, with preserved functional status and quality of life.